Literature DB >> 8503403

Treatment of active Crohn's disease with an oral slow-release budesonide formulation.

M Roth, V Gross, J Schölmerich, B Ueberschaer, K Ewe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8503403

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  4 in total

1.  [Steroid-induced myopathy in left-sided ulcerative colitis. Successful treatment and continued therapy with the topical steroid budesonide].

Authors:  I Caesar; V Gross; M Roth; T Andus; W Hohenberger; J Schölmerich
Journal:  Med Klin (Munich)       Date:  1997-06-15

Review 2.  Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease.

Authors:  C M Spencer; D McTavish
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

3.  Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group.

Authors:  V Gross; T Andus; K W Ecker; A Raedler; K Loeschke; M Plauth; J Rasenack; A Weber; M Gierend; K Ewe; J Schölmerich
Journal:  Gut       Date:  1998-04       Impact factor: 23.059

4.  Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization.

Authors:  H Herfarth; V Gross; T Andus; I Caesar; H Vogelsang; G Adler; H Malchow; A Petri; M Gierend; J Schölmerich
Journal:  Int J Colorectal Dis       Date:  2003-09-09       Impact factor: 2.571
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.